CFB
ALNY icon

Cullen/Frost Bankers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cullen/Frost Bankers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.3M Sell
10,977
-22
-0.2% -$6.63K 0.03% 245
2026
Q1 		$3.64M Sell
10,999
-34
-0.3% -$11.6K 0.04% 232
2025
Q4 		$4.39M Sell
11,033
-10
-0.1% -$4.43K 0.05% 228
2025
Q3 		$5.04M Buy
11,043
+248
+2% +$101K 0.06% 211
2025
Q2 		$3.52M Buy
10,795
+78
+0.7% +$21.6K 0.04% 216
2025
Q1 		$2.89M Buy
10,717
+78
+0.7% +$20K 0.04% 224
2024
Q4 		$2.5M Buy
10,639
+4
+0% +$1.05K 0.03% 230
2024
Q3 		$2.92M Buy
10,635
+80
+0.8% +$20.8K 0.04% 222
2024
Q2 		$2.56M Sell
10,555
-7
-0.1% -$1.1K 0.04% 227
2024
Q1 		$1.58M Buy
10,562
+13
+0.1% +$2.17K 0.02% 266
2023
Q4 		$2.02M Hold
10,549
– – 0.03% 241
2023
Q3 		$1.87M Hold
10,549
– – 0.03% 240
2023
Q2 		$2M Hold
10,549
– – 0.03% 244
2023
Q1 		$2.11M Hold
10,549
– – 0.04% 240
2022
Q4 		$2.51M Hold
10,549
– – 0.05% 225
2022
Q3 		$2.11M Sell
10,549
-400
-4% -$76.3K 0.05% 221
2022
Q2 		$1.6M Hold
10,949
– – 0.04% 254
2022
Q1 		$1.79M Buy
10,949
+400
+4% +$60.9K 0.03% 249
2021
Q4 		$1.79M Hold
10,549
– – 0.03% 251
2021
Q3 		$1.99M Hold
10,549
– – 0.04% 246
2021
Q2 		$1.79M Sell
10,549
-1,176
-10% -$172K 0.04% 258
2021
Q1 		$1.66M Hold
11,725
– – 0.04% 257
2020
Q4 		$1.52M Sell
11,725
-8,284
-41% -$1.11M 0.04% 250
2020
Q3 		$2.91M Sell
20,009
-840
-4% -$119K 0.07% 192
2020
Q2 		$3.09M Sell
20,849
-1,674
-7% -$226K 0.08% 191
2020
Q1 		$2.45M Buy
+22,523
New +$2.6M 0.09% 189

Other funds holding ALNY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Cullen/Frost Bankers's ALNY Position: Q2 2026 in Review

Cullen/Frost Bankers reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.2% in Q2 2026, selling an estimated $6.63K and leaving 10,977 shares worth $3.3M. The position accounts for 0.03% of the portfolio, ranked #245.

Cullen/Frost Bankers first reported a position in ALNY in Q1 2020 and has held it in 26 quarters since. The position peaked at $5.04M in Q3 2025. 365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cullen/Frost Bankers held 10,977 shares of Alnylam Pharmaceuticals worth $3.3M as of Q2 2026.
  • Cullen/Frost Bankers sold 22 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.63K.
  • Alnylam Pharmaceuticals made up 0.03% of Cullen/Frost Bankers's portfolio in Q2 2026, its #245 holding.
  • Cullen/Frost Bankers first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Cullen/Frost Bankers's Alnylam Pharmaceuticals position peaked at $5.04M in Q3 2025.
  • 365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.